Neurokinin‐1 receptor antagonists for prevention of chemotherapy‐related nausea and vomiting in adults
Information
- DOI:
- https://doi.org/10.1002/14651858.CD006844Copy DOI
- Database:
-
- Cochrane Database of Systematic Reviews
- Version published:
-
- 17 October 2007see what's new
- Type:
-
- Intervention
- Stage:
-
- Protocol
- Cochrane Editorial Group:
-
Cochrane Pain, Palliative and Supportive Care Group
- Copyright:
-
- Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Article metrics
Altmetric:
Cited by:
Authors
Contributions of authors
ITL: planning of protocol, protocol write‐up, literature search, data collection and analysis
EB: consensus mediator, text editing, discussion of results
JGB: literature search, data gathering and analysis, review writing
Declarations of interest
None known
Version history
| Published | Title | Stage | Authors | Version |
| 2016 May 25 | Neurokinin‐1 receptor antagonists for prevention of chemotherapy‐related nausea and vomiting in adults | Protocol | Herbert Wong, Aaron M Tejani | |
| 2012 Apr 18 | Neurokinin‐1 receptor antagonists for prevention of chemotherapy‐related nausea and vomiting in adults | Protocol | Herbert Wong, Aaron M Tejani | |
| 2007 Oct 17 | Neurokinin‐1 receptor antagonists for prevention of chemotherapy‐related nausea and vomiting in adults | Protocol | Ivo W Tremont‐Lukats, Eduardo Bruera, Jesús González‐Barboteo | |
| Emetogenicity | Drug |
| HIGH (> 90%) | Cisplatin |
| Dacarbazine | |
| Mechloretamine | |
| Streptozocin | |
| Cyclophosphamide (> 1500 mg/m2) | |
| Actinomycin‐D | |
| Carmustine | |
| MODERATE (30 to 90%) | Carboplatin |
| Oxaliplatin | |
| Cyclophosphamide (<1500 mg/m2) | |
| Lomustine (CCNU) | |
| Daunorubicin | |
| Doxorubicin | |
| Epirubicin | |
| Idarubicin | |
| ARA‐C (Arabinoside cytosine) | |
| Ifosfamide | |
| Irinotecan | |
| LOW (10 to 30%) | Paclitaxel |
| Docetaxel | |
| Mitoxantrone | |
| Topotecan | |
| Etoposide | |
| Pemetrexed | |
| Methotrexate | |
| Mitomycin | |
| Gemcitabine | |
| Cytarabine (< 1000 mg/m2) | |
| Fluorouracil | |
| Bortezomib | |
| Cetuximab | |
| Trastuzumab | |
| Rituximab | |
| Bevacizumab | |
| Busulfan | |
| 2‐chlorodeoxyadenosine | |
| Fludarabine | |
| Vinblastine | |
| Vincristine | |
| Vinorelbine | |
| Bleomycin |
